难治性高血压诊断治疗中国专家共识

2013-05-22 晓静 整理 医学论坛网

  由北京大学人民医院孙宁玲教授、北京大学第一医院霍勇教授、上海市高血压研究所王继光教授等国内知名专家制定的《难治性高血压诊断治疗中国专家共识》(以下简称共识)近日发表于2013年第4期《中华高血压杂志》上。   共识指出难治性高血压(RH)的定义为,在改善生活方式的基础上,应用了合理可耐受的足量≥3种降压药物(包括利尿剂)治疗>1月血压仍未达标,或服用≥4种降压药物血压才能有效控制。目前RH患

  由北京大学人民医院孙宁玲教授、北京大学第一医院霍勇教授、上海市高血压研究所王继光教授等国内知名专家制定的《难治性高血压诊断治疗中国专家共识》(以下简称共识)近日发表于2013年第4期《中华高血压杂志》上。

  共识指出难治性高血压(RH)的定义为,在改善生活方式的基础上,应用了合理可耐受的足量≥3种降压药物(包括利尿剂)治疗>1月血压仍未达标,或服用≥4种降压药物血压才能有效控制。目前RH患病率并不十分清楚,我国还没有准确的流行病学数据。

  共识指出血压测量为RH的主要诊断方法,包括基本诊断方法(诊室血压非同日测量3次以上血压,血压未达标时同时测量双侧上臂血压,两侧血压相差20 mmHg以上时,增测双侧下肢血压)、常规诊断方法(诊室血压测量基础上,行连续家庭自测血压和24h动态血压监测)和家庭自测血压(≥135/85mmHg可诊断)。影响血压控制不良的原因需排除假性RH,如血压测量方法不正确、患者依从性不佳、服用影响血压的药物(如甘草、非甾体抗炎药、口服避孕药、类固醇药物、环孢素、促红素和麻黄素等见表1)、生活方式的因素、高血压药物治疗不充分以及继发性高血压等。RH常见的继发性高血压包括睡眠呼吸暂停综合征、原发性醛固酮增多症、肾实质性高血压、肾血管性高血压和嗜铬细胞瘤,同时应警惕精神心理因素导致的难控制的高血压。

  难治性高血压诊断治疗中国专家共识

  共识还指出,RH治疗包括矫治不良生活方式、药物治疗和有创介入治疗。其中药物治疗使用原则见图1

  难治性高血压诊断治疗中国专家共识

  共识指出降压药物使用的原则为:

  1、RH的基本药物治疗应以肾素血管紧张素系统阻断剂(RASI,ARB或ACEI)联合钙拮抗剂再联合噻嗪类利尿剂的三联治疗方案为主。在此基础上如血压仍不能达标,可依据患者的临床特点联合其他的降压药物(包括β受体阻滞剂、α—β受体阻滞剂或α受体阻滞剂以及醛固酮拮抗剂等)。

  2、在三联的治疗方案中,药物剂量应为常规或双倍的可耐受剂量。

  3、在多药联合治疗的方案中,建议寻求疗效叠加+不良反应少+依从性高的方案,可由有经验的专科医生协助选择。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=38418, encodeId=2cf63841871, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:25:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844406, encodeId=39401844406be, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Wed Dec 04 02:06:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741334, encodeId=2abb1e4133401, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=218a34934063, createdName=12498f1em19(暂无昵称), createdTime=Wed Sep 11 13:06:00 CST 2013, time=2013-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423612, encodeId=21821423612c6, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Fri May 24 00:06:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528250, encodeId=7ee0152825064, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri May 24 00:06:00 CST 2013, time=2013-05-24, status=1, ipAttribution=)]
    2015-10-11 hlycom3356

    感谢作者分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=38418, encodeId=2cf63841871, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:25:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844406, encodeId=39401844406be, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Wed Dec 04 02:06:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741334, encodeId=2abb1e4133401, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=218a34934063, createdName=12498f1em19(暂无昵称), createdTime=Wed Sep 11 13:06:00 CST 2013, time=2013-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423612, encodeId=21821423612c6, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Fri May 24 00:06:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528250, encodeId=7ee0152825064, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri May 24 00:06:00 CST 2013, time=2013-05-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=38418, encodeId=2cf63841871, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:25:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844406, encodeId=39401844406be, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Wed Dec 04 02:06:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741334, encodeId=2abb1e4133401, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=218a34934063, createdName=12498f1em19(暂无昵称), createdTime=Wed Sep 11 13:06:00 CST 2013, time=2013-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423612, encodeId=21821423612c6, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Fri May 24 00:06:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528250, encodeId=7ee0152825064, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri May 24 00:06:00 CST 2013, time=2013-05-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=38418, encodeId=2cf63841871, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:25:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844406, encodeId=39401844406be, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Wed Dec 04 02:06:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741334, encodeId=2abb1e4133401, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=218a34934063, createdName=12498f1em19(暂无昵称), createdTime=Wed Sep 11 13:06:00 CST 2013, time=2013-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423612, encodeId=21821423612c6, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Fri May 24 00:06:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528250, encodeId=7ee0152825064, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri May 24 00:06:00 CST 2013, time=2013-05-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=38418, encodeId=2cf63841871, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:25:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844406, encodeId=39401844406be, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Wed Dec 04 02:06:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741334, encodeId=2abb1e4133401, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=218a34934063, createdName=12498f1em19(暂无昵称), createdTime=Wed Sep 11 13:06:00 CST 2013, time=2013-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423612, encodeId=21821423612c6, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Fri May 24 00:06:00 CST 2013, time=2013-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528250, encodeId=7ee0152825064, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri May 24 00:06:00 CST 2013, time=2013-05-24, status=1, ipAttribution=)]
    2013-05-24 freve

相关资讯

ESH发表RDN治疗难治性高血压立场文件

  欧洲高血压学会(ESH)专家撰写了立场文件,以便就经皮腔内去肾交感神经术(percutaneous transluminal ablation of renal nerves ,RDN)的当前证据、未满足需求和临床推荐加以总结;RDN为治疗顽固性高血压的一种新型治疗策略。肾交感神经激活和中枢神经系统的感觉传入信号为RDN的靶点。临床研

难治性高血压或许并非真难治

 纠正难治性高血压药物治疗的不规范之处   常用降压药物使用不尽合理   药物选择不当 高血压发病机制存在异质性, 在用药选择时应针对患者的发病机制, 坚持个体化原则。   对于容量负荷增加、 交感兴奋、 肾素-血管紧张素系统激活的患者, 须针对性用药或有侧重地增加某类药物的剂量。例如高血压伴慢性肾脏疾病、 糖尿

JACC:去肾神经术治疗难治性高血压患者

  目的  本研究旨在评价去肾神经术(RDN)治疗难治性高血压患者的成本效益和长期临床益处。   背景  难治性高血压累及12%的高血压患者。Symplicity HTN-2随机对照试验显示,RDN可使收缩压从基线时的(178 ± 18)mm Hg降低(32 ± 23)mm Hg。   方法  采用状态转换模型预测RDN和标准治疗对10年及终生卒中、心肌梗死、所有

2012EASO-ESH+联合声明-肥胖和难治性动脉高血压:控制体重的降压获益是否被高估了?

       近期,欧洲肥胖症研究学会(EASO)和欧洲高血压学会(ESH)共同发表了肥胖和难治性动脉高血压联合声明,声明中指出,肥胖症患者易于罹患高血压,常需要更多降压药物治疗,此类患者难治性高血压风险增加。        肥胖和高血压常并存于同一患者,二者间的关联可能因遗传机制等表现出较大的个体差异。肥胖影响

EHJ:ESC支持肾脏去神经化能用于难治性高血压治疗

     日前,欧洲心脏病学会(ESC)发布了一份共识声明,称经导管肾脏去交感神经术(catheter-based renal denervation),也称经导管肾交感神经消融术,可作为高血压治疗的一种备选治疗策略,适用于在生活方式调整和药物治疗后未达到降压目标的耐药性高血压患者。     本声明在线发表于2013

压力反射刺激疗法(BAT)治疗顽固性高血压的新进展

  最近,来自第三军医大学大坪医院心血管病医院、重庆市心血管病研究所的曾春雨在第二届中国高血压大会暨中国医师协会高血压专业委员会年会上报告了压力反射刺激疗法(BAT)治疗顽固性高血压的新进展。   BAT降压机制   刺激颈动脉压力感受器,影响大脑自主神经系统,从而抑制交感神经活性,增强副交感神经活性,最终使心率下降,血管舒张、僵硬度下降,尿钠排出增加,肾素分泌减少。